Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 ...

CHICAGO, IL, USA I 04, 2025 I COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies ...

DÜSSELDORF, Germany I 04, 2025 I Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic ...

BOSTON, MA, USA and LAUSANNE, Switzerland I 4, 2025 I Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces ...

NEW YORK, NY, USA I 03, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of ...

This study will evaluate HCW9302 in patients with moderate to severe alopecia areata. MIRAMAR, FL, USA I 03, 2025 I HCW Biologics Inc. (“HCWB” or the “Company”) ( ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

New at-home RSV treatment represents a potential breakthrough in addressing the burden of respiratory diseases, especially in vulnerable pediatric and elderly ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION ...

SAN MATEO, CA, USA I January 29, 2025 I Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...

— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years — — JOURNAVX is an effective and well-tolerated ...